Abstract
The metabolism of (-)-deprenyl (N-methyl,N-propargylamphetamine) and N-methyl,N-propargylphenylethylamine (MPPE), monoamine oxidase inhibitors with neuroprotective properties, was studied using human liver microsomes and cDNA-expressed cytochrome P450 (CYP) enzymes. The metabolic pathways of MPPE parallel those of (-)- deprenyl, but some marked differences were observed, particularly with regard to the contributions of CYP2B6 and CYP2D6.
Keywords: amphetamine, CYP2B6, propargylamphetamine, cDNA, Metabolism